0000899243-18-016635.txt : 20180614
0000899243-18-016635.hdr.sgml : 20180614
20180614165424
ACCESSION NUMBER: 0000899243-18-016635
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180612
FILED AS OF DATE: 20180614
DATE AS OF CHANGE: 20180614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ferro Kevin
CENTRAL INDEX KEY: 0001299331
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35405
FILM NUMBER: 18899781
MAIL ADDRESS:
STREET 1: C/O KOS PHARMACEUTICALS, INC.
STREET 2: 1001 BRICKELL BAY DRIVE, 25TH FLOOR
CITY: MIAMI
STATE: FL
ZIP: 33131
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MELINTA THERAPEUTICS, INC. /NEW/
CENTRAL INDEX KEY: 0001461993
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 454440364
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 GEORGE STREET
STREET 2: SUITE 301
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
BUSINESS PHONE: 312 767 0291
MAIL ADDRESS:
STREET 1: 300 GEORGE STREET
STREET 2: SUITE 301
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
FORMER COMPANY:
FORMER CONFORMED NAME: CEMPRA, INC.
DATE OF NAME CHANGE: 20120203
FORMER COMPANY:
FORMER CONFORMED NAME: Cempra Holdings, LLC
DATE OF NAME CHANGE: 20090414
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-12
0
0001461993
MELINTA THERAPEUTICS, INC. /NEW/
MLNT
0001299331
Ferro Kevin
C/O VATERA HOLDINGS LLC
499 PARK AVENUE, 23RD FLOOR
NEW YORK
NY
10022
1
0
1
0
Stock Option (right to buy)
7.45
2018-06-12
4
A
0
25000
0.00
A
2028-04-20
Common Stock
25000
25000
D
Stock Option (right to buy)
7.45
2018-06-12
4
A
0
9100
0.00
A
2019-04-20
2028-04-20
Common Stock
9100
9100
D
The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018.
One-third of the shares underlying the stock option will vest and become exercisable on April 20, 2019. The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on April 20, 2019.
/s/ Kevin Ferro
2018-06-14